Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss

Clinical Obesity

Volumn 3, Issue 3-4, 2013, Pages 73-83

  Yassin, A A ^a   Doros, G ^b  

^a Segeberger Kliniken   (Germany)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Obesity; Testosterone; Waist circumference; Weight loss

Indexed keywords

TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ADOLESCENT; AGED; ANDROGEN THERAPY; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TESTOSTERONE BLOOD LEVEL; TREATMENT RESPONSE; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 84890063675     PISSN: 17588103     EISSN: 17588111     Source Type: Journal    
DOI: 10.1111/cob.12022     Document Type: Article

References (51)

1. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013; 10: 245-284.
2. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med 2011; 124: 578-587.
3. Wang C, Jackson G, Jones TH etal. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011; 34: 1669-1675.
4. Saad F, Aversa A, Isidori AM, Gooren LJ. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012; 8: 131-143.
5. Traish AM, Saad F, Feeley RJ, Guay A. The dark side of testosterone deficiency: III. Cardiovascular disease. J Androl 2009; 30: 477-494.
6. Corona G, Rastrelli G, Monami M etal. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011; 165: 687-701.
7. Saad F. Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev 2012; 28 (Suppl. 2): 52-59.
8. Traish AM, Kypreos KE. Testosterone and cardiovascular disease: an old idea with modern clinical implications. Atherosclerosis 2011; 214: 244-248.
9. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009; 30: 10-22.
10. Pasquali R, Casimirri F, Cantobelli S etal. Effect of obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991; 40: 101-104.
11. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2: 675-682.
12. Gapstur SM, Gann PH, Kopp P etal. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. Cancer Epidemiol Biomarkers Prev 2002; 11 (10 Pt 1): 1041-1047.
13. Björntorp P, Rosmond R. The metabolic syndrome - a neuroendocrine disorder? Br J Nutr 2000; 83 (Suppl. 1): S49-S57.
14. Behre HM, Tammela TL, Arver S etal. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012; 15: 198-207.
15. Aversa A, Bruzziches R, Francomano D etal. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study. Aging Male 2012; 15: 96-102.
16. Gupta V, Bhasin S, Guo W etal. Effects of dihydrotestosterone on differentiation and proliferation of human mesenchymal stem cells and preadipocytes. Mol Cell Endocrinol 2008; 296: 32-40.
17. Varlamov O, White AE, Carroll JM etal. Androgen effects on adipose tissue architecture and function in nonhuman primates. Endocrinology 2012; 153: 3100-3110.
18. Maneschi E, Morelli A, Filippi S etal. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol 2012; 215: 347-362.
19. Blouin K, Nadeau M, Perreault M etal. Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clin Endocrinol (Oxf) 2010; 72: 176-188.
20. Hamilton EJ, Gianatti E, Strauss BJ etal. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol 2011; 74: 377-383.
21. Bhasin S, Travison TG, Storer TW etal. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA 2012; 307: 931-939.
22. Srinivas-Shankar U, Roberts SA, Connolly MJ etal. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-650.
23. Svartberg J, Agledahl I, Figenschau Y etal. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008; 20: 378-387.
24. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in non-obese aging men. J Clin Endocrinol Metab 2008; 93: 139-146.
25. Mårin P, Holmäng S, Jönsson L etal. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992; 16: 991-997.
26. Aversa A, Bruzziches R, Francomano D etal. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010; 7: 3495-3503.
27. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity 2013; doi:10.1002/oby.20407 (in press).
28. Kalinchenko SY, Tishova YA, Mskhalaya GJ etal. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol 2010; 73: 602-612.
29. Traish AM, Abdou R, Kypreos KE. Androgen deficiency and atherosclerosis: the lipid link. Vascul Pharmacol 2009; 51: 303-313.
30. Aub JC. The use of testosterone. N Engl J Med 1940; 222: 877-881.
31. Aub JC, Kety SS. Recent advances in testosterone therapy. N Engl J Med 1943; 228: 338-343.
32. Yialamas MA, Dwyer AA, Hanley E etal. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007; 92: 4254-4259.
33. Pitteloud N, Mootha VK, Dwyer AA etal. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636-1642.
34. Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010; 33: 776-783.
35. Nieschlag E, Behre HM (eds). Andrology, 1st edn. Springer: Berlin, Heidelberg, New York, 1997.
36. Bhasin S, Pencina M, Jasuja GK etal. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011; 96: 2430-2439.
37. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762-769.
38. Corona G, Rastrelli G, Monami M etal. Body mass index regulates hypogonadism-associated cv risk: results from a cohort of subjects with erectile dysfunction. J Sex Med 2011; 8: 2098-2105.
39. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081-5088.
40. Camacho EM, Huhtaniemi IT, O'Neill TW etal. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445-455.
41. Zitzmann M, Mattern A, Hanisch J etal. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1, 438 men. J Sex Med 2013; 10: 579-588.
42. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310-320.
43. Morgentaler A. Goodbye androgen hypothesis, hello saturation model. Eur Urol 2012; 62: 765-767.
44. Muller RL, Gerber L, Moreira DM etal. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol 2012; 62: 757-764.
45. Bhasin S, Cunningham GR, Hayes FJ etal. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559.
46. Wang C, Nieschlag E, Swerdloff RS etal. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009; 12: 5-12.
47. Dohle GR, Arver S, Bettocchi C etal. Guidelines on male hypogonadism. Eur Ass Urol 2012. [WWW document]. URL http://www.uroweb.org/gls/pdf/16_Male_Hypogonadism_LR%20II.pdf (accessed April 2013).
48. Morales A, Bain J, Ruijs A, Chapdelaine A, Tremblay RR. Clinical practice guidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int J Impot Res 1996; 8: 95-97.
49. Andriole GL, Crawford ED, Grubb RL III etal.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
50. Schröder FH, Hugosson J, Roobol MJ etal.; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012; 366: 981-990.
51. Tong S-F NC-J, Lee B-C etal. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomized controlled trial. Asian J Androl 2012; 14: 604-611.